卡瑞利珠单抗联合XELOX化疗方案在晚期肝癌患者中的应用效果  

Application Effect of Camrelizumab Combined with XELOX Chemotherapy in Patients with Advanced Liver Cancer

作　　者：董耿[1] 曹旸[2] 乔炳礼[2] DONG Geng;CAO Yang;QIAO Bingli(Pharmacy Department,Zhengzhou Third People's Hospital,Zhengzhou 450000,China;Department of Oncology,Zhengzhou Third People's Hospital,Zhengzhou 450000,China)

机构地区：[1]郑州市第三人民医院药学部,河南郑州450000 [2]郑州市第三人民医院肿瘤内科,河南郑州450000

出　　处：《河南医学研究》2023年第9期1664-1667,共4页Henan Medical Research

基　　金：2019年度河南省医学科技攻关计划(联合共建)项目(LHGJ20191024)。

摘　　要：目的 评价卡瑞利珠单抗联合XELOX化疗方案在晚期肝癌患者中的应用效果。方法 回顾性分析郑州市第三人民医院在2019年6月至2021年12月收治的82例晚期肝癌患者临床资料,根据治疗方法将患者分为对照组(XELOX化疗,41例)和观察组(卡瑞利珠单抗联合XELOX化疗,41例)。两组患者均完成12个月的随访,以治疗3个周期为评价节点,评价指标为近期疗效、肿瘤标志物[甲胎蛋白(AFP)、癌胚抗原(CEA)]、毒副反应以及12个月内生存情况。结果 观察组疾病控制率高于对照组(P<0.05);治疗后,两组AFP、CEA均较治疗前降低,且观察组低于对照组(P<0.05);两组治疗期间毒副反应总发生率比较,差异无统计学意义(P>0.05);随访12个月,观察组总体生存时间长于对照组(P<0.05)。结论 卡瑞利珠单抗联合XELOX化疗方案治疗晚期肝癌患者的近期疗效较好,可降低肿瘤标志物水平,延长生存期,且安全性好。Objective To evaluate the application effect of camrelizumab combined with XELOX chemotherapy in patients with advanced liver cancer.Methods The clinical data of 82 patients with advanced liver cancer admitted to the Zhengzhou Third People’s Hospital from June 2019 to December 2021 were retrospectively analyzed.The patients were divided into the control group(XELOX chemotherapy,41 cases)and the observation group(camrelizumab combined with XELOX chemotherapy,41 cases)according to the treatment methods.Both groups of patients completed 12 months of follow-up,with 3 cycles of treatment as the evaluation node,and the evaluation indicators were short-term efficacy,tumor markers[alpha fetoprotein(AFP),carcinoembryonic antigen(CEA)],toxic side effects and survival within 12 months.Results Compared with control group,the disease control rate in the observation group was higher(P<0.05).After treatment,compared with before treatment,AFP and CEA in both groups were lower,and compared with control group,the observation group was lower(P<0.05).There was no statistically significant difference in the total incidence of side effects in both groups during treatment(P>0.05).After 12 months of follow-up,compared with control group,the overall survival time of observation group was longer(P<0.05).Conclusion Camrelizumab combined with XELOX chemotherapy in the treatment of patients with advanced liver cancer has a good short-term effect,can reduce level of tumor markers,prolong survival period,and is safe.

关 键 词：肝癌 卡瑞利珠单抗 奥沙利铂 卡培他滨 甲胎蛋白 癌胚抗原 毒副反应 

分 类 号：R735.7[医药卫生—肿瘤]